Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C5PA
|
|||
| Former ID |
DCL000983
|
|||
| Drug Name |
Sibenadet
|
|||
| Synonyms |
UNII-N32934RHGW; 154189-40-9; CHEMBL82663; N32934RHGW; Sibenadet [INN:BAN]; AC1L4DOB; SCHEMBL48983; DTXSID50165552; AR-C 68397XX; ZINC36268680; ARC-68397; BDBM50128690; AR-C 68397; 4-Hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-1,3-benzothiazol-2(3H)-one; SB-07499; 2(3H)-Benzothiazolone, 4-hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-; FT-0674579; L001485; 4-Hydroxy-7-{2-[2-(3-phenethyloxy-propane-1-sulfonyl)-ethylamino]-ethyl}-3H-benzothiazol-2-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Discontinued in Phase 3 | [1] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H28N2O5S2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CCOCCCS(=O)(=O)CCNCCC2=C3C(=C(C=C2)O)NC(=O)S3
|
|||
| InChI |
1S/C22H28N2O5S2/c25-19-8-7-18(21-20(19)24-22(26)30-21)9-11-23-12-16-31(27,28)15-4-13-29-14-10-17-5-2-1-3-6-17/h1-3,5-8,23,25H,4,9-16H2,(H,24,26)
|
|||
| InChIKey |
DBCKRBGYGMVSTI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 154189-40-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. | |||
| REF 2 | The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a... Respir Med. 2003 Jan;97 Suppl A:S23-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.